Historical dgx News Stories
DGX: Beat, Dividend Hike, Medicare Cut Risk Ahead.
Quest Diagnostics (DGX) reported a Q4 beat, raised 2026 guidance, boosted its dividend and expanded buybacks—sparking a notable share gain—while looming Medicare reimbursement cuts for hundreds of lab tests create a tangible near-term policy risk.
Quest Diagnostics Jumps After Q4 Beat, Big Buyback
Quest Diagnostics (DGX) surged after reporting a stronger-than-expected Q4 with revenue of $2.81B and adjusted EPS of $2.42, while announcing a 7.5% dividend increase and $1B additional share buyback authorization. Analysts raised price targets and the stock briefly hit a 52-week high, signaling investor confidence tied to durable diagnostic demand and robust capital returns.
DGX Ahead of Earnings: Corewell JV Boosts Outlook!
Quest Diagnostics (DGX) rallied last week as investors weighed an upcoming Q4 & full-year 2025 earnings release and the completed Corewell Health joint venture. Recent price gains, volume upticks, and corporate recognition position DGX ahead of its Feb. 10, 2026 results; near-term direction will hinge on revenue trends, diagnostic volumes, and guidance.